Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Holding(s) in Company

1 Jun 2007 08:00

Flying Brands Limited01 June 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES1. Identity of the issuer or the underlying issuer of existing Flying Brands Limtedshares to which voting rights are attached:2. Reason for the notification (please tick the appropriate box or boxes)An acquisition or disposal of voting rights XAn acquisition or disposal of financial instruments which may result in the acquisition ofshares already issued to which voting rights are attachedAn event changing the breakdown of voting rights3. Full name of person(s) subject to the notification Channel Hotels and Properties Limitedobligation:4. Full name of shareholder(s) (if different from 3.):5. Date of the transaction (and date on which the threshold is 30 May 2007crossed or reached if different):6. Date on which issuer notified: 30 May 20077. Threshold(s) that is/are crossed or reached: 10%8. Notified details: A: Voting rights attached to sharesClass/type of Situation previous to Resulting situation after the triggering transactionshares the Triggering transaction if possible Number of Number of Number of Number of voting rights % of voting rightsusing the ISIN Shares Voting sharesCODE Rights Direct Direct Indirect Direct IndirectUnits comprising 2,410,000 2,410,000 2,610,000 2,610,000 0 10.3% 0.0%ORD 1p and 'A'ORD 0.005p GB0003437059 B: Financial InstrumentsResulting situation after the triggering transactionType of financial Expiration date Exercise/ Conversion Number of voting rights % of votinginstrument Period/ Date that may be acquired if rights the instrument is exercised/ convertedN/A N/A N/A N/A N/A Total (A+B)Number of voting rights % of voting rights2,610,000 10.3% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectivelyheld, if applicable: Proxy Voting:10. Name of the proxy holder: N/A11. Number of voting rights proxy holder will cease to hold: N/A12. Date on which proxy holder will cease to hold voting rights: N/A This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th May 20257:00 amRNSChange of Name
22nd May 20252:23 pmRNSResult of AGM
2nd May 20257:29 amRNSApplication: FDA Breakthrough Therapy Designation
29th Apr 202510:49 amRNSNotice of AGM
25th Apr 20251:46 pmRNSPublication of Annual Report
11th Apr 20253:32 pmRNSPromising Preliminary Results of Phase 1 Study
18th Mar 202510:38 amRNSPlacing to raise £250,000
3rd Feb 20257:00 amRNSIB Expands Distribution with Blackford
22nd Jan 20257:00 amRNSOperations Update
10th Jan 20257:49 amRNSIB and Prism Secure First Installation
20th Nov 20247:00 amRNSImaging Biometrics Expands Distribution
19th Nov 202411:27 amRNSBoard Changes
5th Nov 20247:00 amRNSNew Patent Application and Trading Update
15th Oct 202410:28 amRNSHolding(s) in Company
14th Oct 202412:08 pmRNSHolding(s) in Company
14th Oct 202412:05 pmRNSPDMR dealing and TR1 announcement
11th Oct 202410:42 amRNSAcquisition of Interest by Braveheart
25th Jun 20249:59 amRNSIB Opens Expanded Access Program
14th Jun 20248:38 amRNSClinical Trial Updates
29th May 20243:08 pmRNSResult of AGM
23rd May 20247:00 amRNSMajor East Coast Health System Chooses IB Nimble
20th May 20247:10 amRNSSecond FDA Rare Pediatric Disease Designation
17th May 20247:00 amRNSIB Software Enhances Clinical Decision-Making
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.